Author

L. M. Spring

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:differential expression· 2 Organism:human· 2 Research Focus:cell type annotation· 1 Research Focus:clustering· 1 Approach:experimental assay· 1 Research Focus:gene regulatory network inference· 1 Approach:machine learning (classical)· 1 Assay:proteomics· 1

Frequent Co-Authors

, I. Makhoul· 1 shared A. Bardia· 1 shared A. Bild· 1 shared A. L. Cohen· 1 shared A. M. Egloff· 1 shared A. O'Dea· 1 shared A. R. Parikh· 1 shared B. D. Miller· 1 shared

Activity by Year

2021-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

, I. Makhoul

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Ultrasensitive detection of circulating LINE-1 ORF1p as a specific multi-cancer biomarker

M. S. Taylor, W. Connie, P. C. Fridy, S. J. Zhang, Y. Senussi, J. C. Wolters, W.-C. Cheng, J. Heaps, B. D. Miller, K. Mori, L. Cohen, H. Jiang, K. R. Molloy, B. L. Norden, B. T. Chait, , O. H. Yilmaz

This study develops ultrasensitive assays to detect ORF1p in plasma, showing its potential as a multi-cancer biomarker for early detection and monitoring.

bioRxiv · Jan 25, 2023 · PreprintCancer Biology

Convergent evolution of resistance pathways during early stage breast cancer treatment with combination cell cycle (CDK) and endocrine inhibitors

J. I. Griffiths, J. Chen, P. A. Cosgrove, A. O'Dea, P. Sharma, C. Ma, M. Trivedi, K. Kalinsky, K. B. Wisinski, R. O'Regan, , I. Makhoul, L. M. Spring, A. Bardia, F. R. Adler, A. L. Cohen, , A. Bild

This study examines how breast cancer tumors evolve during early stage treatment with combination CDK and endocrine inhibitors, finding convergent resistance pathways and increased subclonal diversity with combination therapy.

bioRxiv · Jan 19, 2021 · PreprintCancer Biology